Information services provider Thomson Reuters, US, has launched a new forecast tool for the pharma industry, called Thomson Pharma Partnering Forecast. The product seeks to combine competitive intelligence and sales forecast data to enable quick and credible assessment of the sales potential of pipeline and marketed drugs. The product will be demonstrated at two upcoming conferences: Pharma Forecasting Excellence USA in Boston on October 8 and 9, and Bio Europe 2009 in Vienna from November 2-4.
Thomson Pharma Partnering Forecast contains a consensus of analyst forecasts for strategic drugs across the major pharma therapy areas, and combines these forecasts with downloadable, patient-based revenue models for drugs in over 100 indications. The models include transparent assumptions on incidence and prevalence, eligible numbers of patients, estimated timing of approval, pricing, and market share within the indication.
The data is linked with various resources that offer data on the industry pipeline, allowing customers to assess the competitive position of a drug and quickly forecast its sales potential. The product combines data captured from Thomson Reuters’ own drug monitoring team, including assessments of multiple analyst forecasts. It then integrates this data with drug assessments, patient-based forecasts and approval timelines licensed from the company’s recently announced partnership with BioMedTracker.
Search for more such pharma related information in K-Store
Discuss this NEWS
